Catalyst Biosciences Inc Stock
Price
Target price
-
-
-
-
-
?23.10
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Catalyst Biosciences Inc Stock
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Catalyst Biosciences Inc.
With a target price of 23 € there is potential for a 4327.33% increase which would mean more than doubling the current price of 0.52 € for Catalyst Biosciences Inc.
Our community identified positive and negative aspects for Catalyst Biosciences Inc stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Catalyst Biosciences Inc stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Catalyst Biosciences Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Catalyst Biosciences Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Catalyst Biosciences Inc | - | - | - | - | - | - | - |
| Rockwell Medical Inc. | 0.950% | 13.865% | 31.538% | -56.061% | 37.177% | -46.971% | -92.260% |
| Pacira Pharmaceuticals | -1.690% | 6.667% | -18.519% | -20.000% | -18.519% | -45.000% | -68.288% |
| Twist Bioscience Corp | -3.700% | 1.764% | 26.532% | -29.051% | 30.485% | 37.469% | -76.854% |
Comments
Crescent Biopharma (NASDAQ:CBIO) is now covered by analysts at Guggenheim. They set a "buy" rating and a $35.00 price target on the stock.
Show more
Ratings data for CBIO provided by MarketBeat
Crescent Biopharma (NASDAQ:CBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Show more
Ratings data for CBIO provided by MarketBeat
Crescent Biopharma (NASDAQ:CBIO) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $26.00 price target on the stock.
Show more
Ratings data for CBIO provided by MarketBeat
